Protagonist Therapeutics Stock Probability of Future Stock Price Finishing Under 41.46
| PTGX Stock | USD 40.69 0.77 1.86% |
Protagonist |
Protagonist Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Protagonist Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Protagonist Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Protagonist Therapeutics generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 60 M. Net Loss for the year was (78.95 M) with profit before overhead, payroll, taxes, and interest of 26.58 M. | |
| Protagonist Therapeutics currently holds about 291.89 M in cash with (70.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.95. | |
| Protagonist Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors |
Protagonist Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Protagonist Stock often depends not only on the future outlook of the current and potential Protagonist Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Protagonist Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 56.8 M | |
| Cash And Short Term Investments | 341.6 M |
Protagonist Therapeutics Technical Analysis
Protagonist Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Protagonist Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Protagonist Therapeutics. In general, you should focus on analyzing Protagonist Stock price patterns and their correlations with different microeconomic environments and drivers.
Protagonist Therapeutics Predictive Forecast Models
Protagonist Therapeutics' time-series forecasting models is one of many Protagonist Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Protagonist Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Protagonist Therapeutics
Checking the ongoing alerts about Protagonist Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Protagonist Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Protagonist Therapeutics generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 60 M. Net Loss for the year was (78.95 M) with profit before overhead, payroll, taxes, and interest of 26.58 M. | |
| Protagonist Therapeutics currently holds about 291.89 M in cash with (70.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.95. | |
| Protagonist Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors |
Additional Tools for Protagonist Stock Analysis
When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.